Sinco Pharms Hldg Ltd (6833) fair value: what the stock is really worth
We calculate from audited financials what Sinco Pharms Hldg Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Sinco Pharms Hldg Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range HK$0.1450 – HK$2.06 · fair‑value band HK$0.3200 – HK$0.5900 · the HK$0.1450 price screens below the HK$0.4500 fair value. Dashed = 300-day average. As of Sep 13, 2026.
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China.
Show more
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers human albumin serum under the Octapharma, Octapamma, and Octenor name for the treatment of premature infants, hypovolemia, hypoproteinemia, neonatal hyperbilirubinemia, acute respiratory distress syndrome, cardiopulmonary bypass, special types of hemodialysis, and plasma exchange. It also provides Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections. In addition, it is involved in the research, development, and sale of pharmaceutical products; provision of warehouse facilities for pharmaceutical products; research and manufacturing of aesthetic medicine; international trade activities; consultation services for medical and biological technology; market promotion; and medical beauty services. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited operates as a subsidiary of Risun Investments Limited.
Stock analysis
Sinco Pharms Hldg Ltd (6833) currently trades at HK$0.1450, while our model-based Fair Value estimate is HK$0.4500, implying the stock looks roughly 67.8% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$1.21 per share, and 24 of the 26 models we run sit above the HK$0.1450 price.
Bear case: the Asset-Based group reads lowest at HK$0.2300, and 2 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: HK$0.3200 (bear) to HK$0.5900 (bull), the price of HK$0.1450 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Sinco Pharms Hldg Ltd reported revenue of HK$2.1B in FY2025 versus HK$2.0B in FY2021, a compound +0.7%/yr. Reported net income was HK$34.9M in FY2025, compounding −28.7%/yr from FY2021.
Key figures
Market cap HK$325M (≈ $41.5M) · P/E ratio 8.0 · P/S ratio 0.13 · EPS (TTM) HK$0.0100 · Dividend yield 1.4% · Net margin 1.7% · Return on equity 5.1% · Return on assets (EBIT) 6.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 210%, 6833 screens cheaper than that median.
Fair Value models
Bear HK$0.3200Fair Value HK$0.4500Bull HK$0.5900
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (HK$0.0056 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−26.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−23.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−24.5%
Dividend (yield on the price)1.4%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−25% vs −11%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 4%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 79 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score55 · Above median
Fair Value upside+139% · Top 25%
Profitability
Return on equity (TTM)5% · Below median
Return on assets2% · Below median
Net margin (TTM)2% · Above median
Operating margin (TTM)3% · Below median
Growth and dividend
Revenue growth−31% · Bottom 25%
Dividend yield (TTM)1.4% · Below median
Valuation Multiplesvs Medical Distribution median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sinco Pharms Hldg Ltd (6833) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of HK$0.4500 versus a price of HK$0.1450, about +210% upside (undervalued).
What is the fair value of 6833?
Our model-based fair value for Sinco Pharms Hldg Ltd is HK$0.4500 (as of Sep 13, 2026), built from audited fundamentals. The current price: HK$0.1450.
What is the quality score of 6833?
Sinco Pharms Hldg Ltd has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sinco Pharms Hldg Ltd (6833)?
Our model-based price target is the fair value of HK$0.4500 (as of Sep 13, 2026) from 26 valuation models. Cautious scenario HK$0.3200, optimistic scenario HK$0.5900. It is a calculation from audited fundamentals, not an analyst target.
What is the Sinco Pharms Hldg Ltd stock forecast for 2026?
Our models put fair value at HK$0.4500, about +210% upside versus a price of HK$0.1450 (undervalued). Cautious scenario HK$0.3200, optimistic scenario HK$0.5900. The calculation is refreshed regularly with new filings.
What is the revenue of Sinco Pharms Hldg Ltd (6833)?
Sinco Pharms Hldg Ltd reported trailing-twelve-month revenue of about HK$2.1B (latest available figure, as of Sep 13, 2026).
Does Sinco Pharms Hldg Ltd pay a dividend?
Sinco Pharms Hldg Ltd currently shows a dividend yield of about 1.38% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Sinco Pharms Hldg Ltd (6833)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sinco Pharms Hldg Ltd it is HK$0.4500 per share (as of Sep 13, 2026), against a price of HK$0.1450. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Sinco Pharms Hldg Ltd stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 6833 trades below its calculated fair value: price HK$0.1450, fair value HK$0.4500, a gap of about +210% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6833?
No. The price is what the market pays today (HK$0.1450); the fair value is what the company's own numbers justify (HK$0.4500). For Sinco Pharms Hldg Ltd the two are HK$0.3050 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sinco Pharms Hldg Ltd worth?
The market values Sinco Pharms Hldg Ltd at about HK$325M (market capitalisation, as of Sep 13, 2026). Per share that is HK$0.1450; our models calculate a fair value of HK$0.4500 per share.
What do the bullish and bearish scenarios say about 6833?
Our models span a range for Sinco Pharms Hldg Ltd: cautious scenario HK$0.3200, base HK$0.4500, optimistic HK$0.5900 per share (as of Sep 13, 2026, price HK$0.1450). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 6833?
Sinco Pharms Hldg Ltd trades at a price-to-earnings ratio of 8.0 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$0.4500 is built from several models across several years. Other multiples: P/B 0.5, P/S 0.2.
How solid is the balance sheet of Sinco Pharms Hldg Ltd (6833)?
Balance-sheet figures for Sinco Pharms Hldg Ltd (as of Sep 13, 2026): return on equity 5.1%. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 6833 from its 52-week high?
Sinco Pharms Hldg Ltd trades at HK$0.1450, about 48% below its 52-week high of HK$0.2776 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.4500 is for.
Which stocks are comparable to Sinco Pharms Hldg Ltd?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sinco Pharms Hldg Ltd stock attractive at the current price?
The data as of Sep 13, 2026: price HK$0.1450, calculated fair value HK$0.4500 (+210%), Quality Score 55/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 6833 calculated?
We run Sinco Pharms Hldg Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$0.4500, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Sinco Pharms Hldg Ltd currently trades 210 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Sinco Pharms Hldg Ltd right now?
The price is below even our cautious bear case (HK$0.3200). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (55/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (HK$0.3200 to HK$0.5900) leaves room in how you read the outcome.
Where does the earnings growth of Sinco Pharms Hldg Ltd (6833) come from?
Earnings per share at Sinco Pharms Hldg Ltd grew −7.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.8 %, EBIT margin −8.7 %, tax rate −5.5 %, residual (interest, one-offs) +1.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Sinco Pharms Hldg Ltd
How large is the market capitalisation of Sinco Pharms Hldg Ltd (6833)?
The market capitalisation of Sinco Pharms Hldg Ltd is HK$325M (≈ $41.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sinco Pharms Hldg Ltd (6833)?
The price-to-sales ratio of Sinco Pharms Hldg Ltd is 0.13 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sinco Pharms Hldg Ltd (6833)?
Earnings per share at Sinco Pharms Hldg Ltd are HK$0.0100 (price ÷ EPS = P/E 8.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sinco Pharms Hldg Ltd (6833)?
The dividend yield of Sinco Pharms Hldg Ltd is 1.4% (payout 20.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sinco Pharms Hldg Ltd (6833)?
The net margin of Sinco Pharms Hldg Ltd is 1.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sinco Pharms Hldg Ltd (6833)?
The return on equity (ROE) of Sinco Pharms Hldg Ltd is 5.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sinco Pharms Hldg Ltd (6833)?
On an EBIT basis the return on assets of Sinco Pharms Hldg Ltd is 6.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sinco Pharms Hldg Ltd (6833)?
The operating margin of Sinco Pharms Hldg Ltd is 2.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sinco Pharms Hldg Ltd (6833)?
Revenue at Sinco Pharms Hldg Ltd is growing −31.3% versus a year earlier (3y avg −2.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sinco Pharms Hldg Ltd (6833)?
Earnings per share at Sinco Pharms Hldg Ltd are growing −39.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sinco Pharms Hldg Ltd (6833) generate?
The free cash flow of Sinco Pharms Hldg Ltd is HK$160M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sinco Pharms Hldg Ltd (6833) hold?
Sinco Pharms Hldg Ltd holds more cash than debt, HK$191M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Sinco Pharms Hldg Ltd in the live analysis
One click puts Sinco Pharms Hldg Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
